They just bought IM-250

Alfasigma to invest up to $125M in parenteral adibelivir (IM-250) for HSV encephalitis

Alfasigma has secured exclusive rights from Innovative Molecules and plans to invest up to $125 million to develop parenteral adibelivir for the treatment of HSV encephalitis, an ultra-rare manifestation of herpes infection.